Producers looking for ways to protect pigs against enzootic pneumonia caused by Mycoplasma hyopneumoniae now have a more flexible option. Ingelvac MycoFlex from Boehringer Ingelheim Vetmedica Inc., aids in the reduction of enzootic pneumonia, providing quick immunity and long-lasting protection.
“Ingelvac MycoFlex will reduce clinical signs associated with Mycoplasma hyopneumoniae,” says Reid Philips, DVM, senior technical manager, swine respiratory biologics for BIVI. “Vaccination also will reduce the lung lesions and pneumonia and help improve overall pig health and performance.”
Enzootic pneumonia caused by Mycoplasma hyopneumoniae is a widespread swine disease that can affect pigs of all ages. However, it is primarily a disease of growing and finishing pigs, and it’s characterized by a dry cough and impaired growth performance.
“The single-dose formulation requires less time and manual labor, puts less stress on the pigs, and is compatible with Pork Quality Assurance guidelines,” according to Gary Robertson, BIVI spokesman. BIVI research data also confirm that Ingelvac MycoFlex and Ingelvac CircoFlex can be mixed with confidence and administered immediately (within four hours) as a single, labor-saving 2-mL injection for proven Mycoplasma and circovirus protection.
Ingelvac MycoFlex can be used with pigs as young as 3 weeks of age through the time when pigs leave the nursery. The objective is to vaccinate pigs at least two weeks prior to exposure to Mycoplasma hyopneumoniae. BIVI encourages a producer to consult with his or her veterinarian to determine the optimum vaccination timeframe for each operation.
For more information about Ingelvac MycoFlex, contact Boehringer Ingelheim at